acalabrutinib,zanubrutinib
beigene,astrazeneca
['acalabrutinib', 'zanubrutinib']
treatment with zanubrutinib showed clinically meaningful benefit to a large majority of efficacy-evaluable patients with b-cell malignancies who were intolerant to acalabrutinib, according to updated results from the bgb-3111-215 trial. #ash22 
Oncology news and insights from leading researchers and cancer centers.